Genmab — September 2016
-
Data på ofa ms i 2019
-
Fantastisk cd3/cd20 antibody
-
Spektakulere data i hexabody dr5/dr5
-
50% ejerskab i næste vinder
-
Men intet om tisotumab. Tiden gar også knap
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind